Since recently experts haven’t had single opinion on the volume and dynamics of the Russian pharmaceutical market as a whole as well as its main sectors. Aggregate market value in 2013 is evaluated at 750–80 bn Rbls, consisting of three major segments: retail (out-of-pocket), hospital and reimbursable drug coverage.

Retail sector is estimated at 609bn Rbls, growing at 14% by DSM Group and lower market figure of 571 bn Rbls and 9% growth is given by IMS health. Hospital market assessments are even further apart ranging from 183bn Rbls by DSM, growing at 17% vs 2012 to only 127bn Rbls by IMS health with 1% decline vs previous year.

With regards to LLO segment (Reimbursable drug coverage) there is more unanimous evaluation at 84–83 bn Rbls and slow one digit growth vs 2012.

Further speculations and market forecasts are hard to make given political situation in the Ukraine.